Press Releases
Gilead Sciences and the World Health Organization Announce Five-Year Visceral Leishmaniasis Collaboration
Gilead Sciences Inc announced it has entered into a partnership with the World Health Organization (WHO) to provide $20 million in funding and drug donations over five years to expand access to diagnostic services and treatment for visceral leishmaniasis...
Press Releases
Vital to Showcase Enterprise Interoperability for Improved Clinical Care and Business Intelligence at HIMSS Asia Pacific
Vital Images, Inc. a Minneapolis-based advanced medical imaging and informatics company, will feature its enterprise interoperability solutions at the HIMSS Asia Pacific annual conference in booth 412, 23-26 August in Bangkok, Thailand. Vital's healthcare imaging informatics...
Press Releases
RRC Introducing The next-generation in chemical-free moisture analysis Computrac Vapor Pro XL
Arizona Instrument LLC is proud to announce the release of the Computrac® Vapor Pro® XL – the latest in a long line of accurate, reliable and easy to use moisture analyzers. About the Vapor Pro® XLThe...
Press Releases
FDA Approves Troxyca ER Capsules with Abuse-Deterrent Properties for the Management of Pain
Pfizer Inc announced that the U.S. Food and Drug Administration (FDA) has approved Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily. ...
Press Releases
AstraZeneca provides update on Phase III trial of Selumetinib in non-small cell lung cancer
 AstraZeneca announced results from the Phase III SELECT-1 trial of the MEK 1/2 inhibitor, selumetinib, in combination with docetaxel chemotherapy as 2nd-line treatment in patients with KRAS mutation-positive (KRASm) locally-advanced or metastatic non-small cell lung cancer (NSCLC). ...
Press Releases
Biogen Announces Bioverativ as Name of New Hemophilia-Focused Company
Biogen announced that Bioverativ will be the name of the standalone, publicly-traded global biotechnology company that it expects to launch in early 2017. Bioverativ will be focused on the discovery, research, development and commercialization of treatments for hemophilia and...
Press Releases
Takeda Receives Marketing Authorization in Canada for NINLAROâ„¢ (ixazomib) in Relapsed/Refractory Multiple Myeloma
Takeda Pharmaceutical Company Limited announced Takeda Canada has received approval from Health Canada for NINLAROâ„¢ (ixazomib) capsules in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read